The clinical success of monoclonal antibodies to treat diseases across nearly every therapeutic area has spurred advances in bispecific antibody technology with the goal of cost-effectively combining various therapies or providing novel mechanisms for disease intervention. Many novel bispecific antibodies are now in clinical development or the late pre-clinical setting. A new horizon exists for novel molecular entities with the ability to bind three or more antigens. Here we describe the production and characterization of novel trispecific antibody-like proteins denoted 'OrthoTsAbs' that self-assemble through the application of engineered antibody domain interfaces.
Introduction
Monoclonal antibodies (mAbs) are having a profound impact on human health and disease management. Over 50 mAbs are FDA approved and 100 s are in clinical trials (Ecker et al., 2015; Reichert, 2017) . However, mAbs only recognize a single antigen, which places a limitation on the extent to which they can intervene diseases such as cancer and autoimmunity that emerge from complex and multifaceted molecular and cellular disregulation. Bispecific antibodies (BsAbs) have been the next step to achieve improved efficacy. BsAbs enable combination therapy in a single molecule, and also provide the capacity for enhanced cell specificity (Mazor et al., 2015 (Mazor et al., , 2017 , receptor cross-linking (Weidle et al., 2014) , immune cell redirected tumor killing (Huehls et al., 2015) and many other complex mechanisms to intervene in disease. Methodologies for generating stable, manufacturable BsAbs with mAb-like pharmacokinetics and potential immune cell recruitment through the Fc have significantly advanced in recent years (Brinkmann and Kontermann, 2017) . These novel BsAb represent a next wave of therapeutics with the goal of achieving improved efficacy with over 50 moieties currently in clinical development (Brinkmann and Kontermann, 2017) .
There are many conceivable and compelling reasons to go beyond BsAb binding to engage more than two antigens. For instance, one could conceive enhancing specific tumor targeting using multiple tumor associated antigens while still engaging immune cells for redirected lysis. CAR-T cells have been engineered that bind multiple tumor restricted antigens that either restrictively trigger T cell activation upon engaging two tumor targets or mitigate tumor escape mechanisms by targeting multiple antigens (Kloss et al., 2013; Hegde et al., 2016) . Under selective pressure via the targeting of a single growth and/or survival pathway, tumor cells may switch to one or more additional and redundant pathways to thrive (Van Emburgh et al., 2014; Jonas et al., 2016; Kjaer et al., 2016) . A prime example is the co-expression or upregulated expression of HER-2 or cMet receptor tyrosine kinases in head and neck cancer in response to EGFR mAb therapy (Burtness et al., 2013) . Targeting all three receptors simultaneously may more effectively repress tumor escape or survival. Checkpoint inhibitors have become a new paradigm for immunogenic cancer types having demonstrated longterm remissions or cures in a modest subset 10-20% of melanoma and non-small cell lung cancer patients. These responses can be improved by combination of checkpoint inhibitors/agonists, albeit with concomitant increases in autoimmune side-effects (Larkin et al., 2015; Dempke et al., 2017) . For example, combinations of mAbs directed to PD-1, CTLA-4 and CD137 with or without anti-CD19 have the ability to ablate multiple syngeneic tumors in mice (Dai et al., 2015) . Multi-modal targeted therapy in the autoimmune setting also holds promise; however, clinical combinations and bispecifics in this space are still in their infancy. In infectious diseases, targeting multiple antigens or epitopes can lead to improved efficacy as has been demonstrated for HIV, influenza and even Ebola (Chen et al., 2013; Dixit et al., 2016; Madelain et al., 2016) . In all these cases, an antibody-like molecule with the ability to engage three or more epitopes or antigens has the potential to achieve superior efficacy.
Developing therapeutics with the ability to bind three or more antigens significantly raises the complexity of these proteins. Trispecific antibodies (TsAbs) have been described that use multiple antibody variable domain fragments (Castoldi et al., 2012; Dimasi et al., 2015; Schmohl et al., 2016; Egan et al., 2017) . Antibody fragments such as single chain Fvs (scFvs) can have stability and solubility limitations, and when using multiple fragments, these limitations can be compounded and require significant engineering (Demarest and Glaser, 2008) . Alternate scaffold proteins could also be recombinantly linked to an antibody or each other to produce multispecific moieties (Binz et al., 2005) . Here, we describe an approach to recombinantly combine multiple antibody Fab moieties to produce TsAbs with varied molecular geometry. A major challenge with utilizing full antibody Fab moieties as building blocks for BsAbs is achieving correct heavy chain (HC)/light chain (LC) pairing when co-expressing multiple heavy and light chains simultaneously. This has remained a challenge even for BsAbs , which is compounded in TsAbs that comprise three unique Fab moieties. We utilize existing Fab interface designs geared towards native-like IgG BsAb production, denoted 'Orthogonal Fabs' (Lewis et al., 2014; Leaver-Fay et al., 2016; Froning et al., 2017) , to induce correct chain pairing within TsAbs that we denote 'OrthoTsAbs'. We evaluate six OrthoTsAb formats with Fabs from pertuzumab, matuzumab, and MetMAb (HER-2×EGFR×cMet TsAbs) and, as a second case study, the same six OrthoTsAb formats using Fabs from nivolumab, urelumab, and ipilimumab (PD-1×CD137×CTLA-4 TsAbs).
Materials and Methods

Subcloning and transient CHO expression
The amino acid sequences of the anti-HER-2 (pertuzumab), anti-EGFR (matuzumab) and anti-cMet (MetMAb) antibodies has been described (Lewis et al., 2014) . The anti-PD-1 (nivolumab), anti-CD137 (urelumab) and anti-CTLA-4 (ipilimumab) sequences were from the patent literature (WO 2016/029073 A2; US 2002/0086014 A1). The Fab and full-length HC coding regions were synthesized using PCR from previous constructs or large gblocks (IDT) with overlapping overhangs and polymerase chain reactions as described (Casimiro et al., 1997; Lewis et al., 2014) . The Fab and HC pieces were assembled using a three-way ligation with the existing HindIII (5′) and EcoRI (3′) expression cassette restriction sites and an internal BamHI site designed within the (G 4 S) 4 linker regions in a mammalian expression vector (Lonza). The cognate Fab HCs and Fab LCs were also constructed by overlapping gblock PCR and cloned into the same mammalian expression plasmid using the same restriction sites. The plasmid constructs for each OrthoTsAb were transiently transfected in 100 mL CHO for recombinant protein secretion into the media as described (Rajendra et al., 2017) . For all the OrthoTsAb formats, whether they required five plasmid transfection or four plasmid transfection, equal amounts of DNA were transfected for each plasmid up to a final DNA concentration of 3.2 μg/mL CHO cells (Rajendra et al., 2017) . Transfected cells were grown at 37°C in a 5% CO 2 incubator while shaking at 125 r.p.m. for 5 days. Supernatants were harvested by centrifugation at 10 000 r.p.m. for 5 min followed by passage through 2 μm filters.
Purification and biochemical characterization
CHO supernatants containing each of the IgG-Fc containing OrthoTsAbs were loaded to a 5 mL HiTrap Mab select sure (GE) column at 5 mL/min using an AKTA explorer (GE Healthcare). The columns were washed using 25 mL phosphate buffered saline at pH 7.4 (PBS), followed by elution with 25 mL of a 20 mM citric acid buffer at pH 3.0 (all at 5 mL/min). CHO supernatants containing OrthoTsAbs lacking an IgG-Fc were passed over a 5 mL Hitrap His (GE) at 5 mL/min. The column was washed with 25 mL PBS, followed by 25 mL of 25 mM imidazole in PBS, pH 7.5. The protein was eluted with 25 mL 0.5 M imidazole in PBS. Each TsAb was further purified by passage over a Superdex 200 16 mm × 60 cm column (Millipore Sigma) with PBS as the running buffer. The main peak based on UV 280 nm was collected and concentrated in PBS. The OrthoTsAbs were characterized biochemically by running 1-5 μg protein on SDS-PAGE gels (4-12% Bis-Tris) with the Mark 12 protein molecular weight standard (Invitrogen). Reducing conditions were induced by the addition of 1 μL 1 M DTT. Disulfide rearrangements under non-reducing conditions were blocked using N-ethylmaleimide (Taylor et al., 2006) . The oligomeric states of the OrthoTsAbs were assessed using analytical SEC. For each sample, between 20 and 60 μg material was injected over a Yarra-SEC-3000 analytical SEC HPLC (7.8 × 300 mm 2 ) column (Phenomenex) equilibrated in 10 mM phosphate, 150 mM NaCl, 0.02% NaN 3 , pH 6.8, using an Agilent 1100 HPLC system equipped with an autosampler and in-line UV spectrometer. UV 280 nm data were collected and analyzed using HPCHEM (Agilent). 
Intact mass spectrometry
Intact mass was measured using an Agilent 1290 HPLC coupled to an Agilent 6230 ESI-TOF mass spectrometer. Each sample (2 μg) was desalted on a MassPREP MicroDesalting Column 2.1 × 5 mm 2 (Waters) loaded with 80% mobile phase A (0.2% formic acid), and gradient eluted to 80% mobile phase B (0.2% Formic acid in acetonitrile) in 2 min and held for 1 min. The same gradient was repeated as a wash step. The flow was bypassed for 3 min before the eluent was diverted into the mass spectrometer. The Agilent 6230 was run in positive ion mode at 4000 V, skimmer at 65 V, fragment or at 300 V, gas temperature at 350°C, dry gas at 12 psi and nebulizer gas at 40 psi. The MS scan was from 600 m/z to 4000 m/z with 1 scan/s. Data were collected from 3 to 10 min and the protein molecular weight was determined by summing the TIC peak spectra followed by deconvolution with Agilent Bioconfirm Mass Hunter v7.0. The deconvolution for the non-reduced sample was from 80 to 210 kDa with a peak width of 1.5 Da using 20 iterations and a 1 Da step.
Surface plasmon resonance
All surface plasmon resonance experiments were performed on a Biacore3000 or Biacore8K (GE Healthcare) using an HBS-EP running buffer at 25°C. An anti-human kappa polyclonal antibody (Southern Biotech, Cat#2060-01) was immobilized to 10 000 RU on CM5 sensorchip surfaces using the standard amine coupling algorithms within the software. A reference surface was prepared by Fig. 2 Biochemical characterization of the OrthoTsAbs. Reduced (A and D) and non-reduced (B and E) SDS-PAGE and analytical SEC (C and F) of the TsAbs directed to HER-2/EGFR/cMet and PD-1/CD137/CTLA-4, respectively. In the SEC plots, the solid lines are chromatograms of the TsAb_C_HL, TsAb_N_H, and TsAb_HHH, while the dotted lines are chromatograms of TsAb_C_L, TsAb_N_L, and TsAb_HHL. direct immobilization using ethanolamine. Each OrthoTsAb was captured (100 nM onto the chip surface by injection of 20 μL at a 5 μL/min flowrate). The antigens were subsequently injected (50 nM in HBS-EP, 40 μL injections, 10 μL/min) at 10 min intervals. Soluble human HER-2 and cMet extracellular domain (ECD) proteins were purchased from Speed BioSystems (Cat#: YCP1045 and YCP2247; His-tagged) and soluble human CTLA-4 ECD protein was purchased from SinoBiologics (Cat#11 159-H08H-50, His-tagged). Soluble human EGFR, PD-1 and CD137 ECD proteins (His-tagged) were produced in-house (Lewis et al., 2014) . The sensorchip surface was regenerated by increasing the flowrate to 50 μL/min and performing two successive 5 μL injections of 0.1 M glycine, pH 1.5. Kinetic binding curves were processed using the BiaEval software. Each curve was double referenced using the matching ethanolamine surface curve and a separate kinetic curve performed entirely with buffer.
Results
OrthoTsAb design
The TsAbs were designed with varied geometries. Each construct contains three unique HC/LC moieties that must pair correctly to be fully functional. TsAbs were evaluated with or without an IgG Fc. The existence of the IgG-Fc moiety should impart improved pharmacokinetics through binding FcRn and recycling away from the lysosomal cellular compartment (Roopenian and Akilesh, 2007) . For Fc-containing TsAbs, we preferred to maintain a native-like antibody moiety within the TsAb construct and monovalent binding. We believe monovalent binding to each antigen would limit the overall molecular weight and ultimately allow for more precise affinity tuning to each target while reducing the potential for large immune complexes formation. To achieve monovalent binding of all three Fabs, we introduced an Fc heterodimerization design (20.8.34) from a previously described design effort (Leaver-Fay et al., 2016). We evaluate both N-and C-terminal Fab fusions to the native-like antibody moiety. Schematic diagrams of the varied TsAb formats that were constructed are shown in Fig. 1 . Some of the constructs use HC and LC polypeptide fusions in an effort to determine whether this might improve proper assembly. The IgG formats C-terminally fused with a Fab were denoted C_HL or C_L based on the polypeptide linkages that were evaluated, while the N-terminally fused TsAbs were denoted N_H and N_L. The non-IgG-Fc bearing TsAbs were made in a tandem Fab format and were denoted HHH and HHL. Sequences of the various HCs and LCs that comprise each of the TsAbs are provided in Fig. S1 .
To induce correct HC/LC pairing, we combined multiple Fab interface designs including previously described variable domain interface designs as well as redesigned CH1/Cλ and CH1/Cκ interfaces (Lewis et al., 2014; Froning et al., 2017) . An important aspect to consider is that without designs to induce specific HC/LC pairing, the expected percentage of correctly assembled TsAb for those without a heterodimeric Fc is <5%. The addition of a heterodimeric Fc to each TsAb reduces this expected assembly by >50% given that 'half-antibody', non-covalently linked head-to-tail homodimer, can be a significant impurity on top of the normal homodimeric Fc species (Elliott et al., 2014; Leaver-Fay et al., 2016) . Thus, achieving high levels of appropriately assembled Fab-based TsAbs is a big hurdle (Lewis et al., 2014; Froning et al., 2017) .
Expression and Biophysical Characterization of the OrthoTsAbs
All 12 TsAbs (6 HER-2xEGFRxcMet TsAbs and 6 PD-1×CD137×CTLA-4 TsAbs) were produced at small scale to evaluate their expression and inherent assembly. Each of the TsAbs contains between four and five separate polypeptide chains that must assemble properly to be fully functional and stable. All the TsAbs were transiently expressed at the 100 mL scale in CHO by co-transfection of single vectors encoding each of the particular HC and LC polypeptides and purified as described in Materials and Methods. TsAbs. An asterisk (*) is shown above the '½ antibody' impurity that results if one of the two HCs expresses at a higher level than the other. This impurity is only observed (or possible) for TsAbs designed with a heterodimeric Fc. The bottom panel (B) provides the deconvoluted spectrum of each TsAb in the region where both assembly and misassembly is predicted to occur. Asterisks (*) are shown above the species predicted to have mispaired LC components. An overview of the extent of mispairing within each of the TsAbs based on the areas of each deconvoluted peak is provided in Table I .
The TsAbs all adopted their intended forms. Analysis on denaturing gels showed that each TsAb was predominately at the expected molecular weight. Under reducing conditions, the TsAbs all displayed the expected molecular weights for each of their polypeptide components ( Fig. 2A, B, D, E) . The hydrodynamic behavior of the TsAbs was assessed using analytical SEC. The minor presence of 'half-antibody' (non-covalently linked Fc-homodimer (Elliott et al., 2014; Leaver-Fay et al., 2016) ) can be observed in most of the Fc-containing TsAbs. The PD-1×CD137×CTLA-4 C_HL, C_L and HHL proteins showed less ideal hydrodynamic behavior with multiple hydrodynamic species by SEC (Fig. 2F) . However, the remainder of the TsAbs, including all the HER-2×EGFR×cMet TsAbs, were predominately monodisperse with elution times within the expected range for their respective molecular weights (Fig. 2C) .
We next performed intact mass spectrometry on the TsAbs to assess the level of correct chain pairing that should translate into their desired binding capacity. Example spectra of the HER2×EGFR×cMet TsAbs are provided in Fig. 3 . Peaks at the appropriate molecular weights are clearly the predominate species in all the spectra. The presence of half-antibody is apparent at different levels in all the Fc-containing TsAbs, but is absent, as expected, in the HHH and HHL formats (Fig. 3A) . Only when zooming in on the main peaks is it clear how much mispaired HC/LC species exist. Encouragingly, the main peak is the expected species for every TsAb that was generated (Fig. 3B) , indicating that the HC/LC and Fc-heterodimer designs were able to influence proper HC/LC pairing far beyond what would be expected without any interference (~2-5%). With the understanding that different protein species may have different ionization potentials, we still used the relative deconvoluted peak areas to provide a semi-quantitative evaluation of the different species within the LCMS spectra. Using this method, none of the TsAbs fell below 50% correct HC/LC and HC/HC pairing ( Table I ). The majority of the TsAbs demonstrated >75% correct HC/LC and HC/HC assembly with a few achieving >90% correct assembly (Table I) . While some TsAbs assembled better than others, it is difficult to predict based on the data one with only two sets of TsAbs whether any of the formats might lead to superior assembly. Given that all the TsAbs showed a majority of proper assembly, perhaps the biological properties imparted by each format may be the more important feature when choosing a format for a particular therapeutic concept.
Finally, we evaluated the thermal stability of the TsAbs using DSC. Scans are shown in Fig. S1 . Clearly, based on Table I , the TsAbs have between 0 and 50% chain mispairing and significant half-antibody that was not removed using affinity followed by size exclusion chromatography. The DSC scans show major peaks for the HER2×EGFR×cMet TsAbs with midpoints of thermal unfolding (T m s) between 60-80°C, similar to natural IgGs (Garber and Demarest, 2007) with the first major peak being at the low end (Fig. S1) . The PD-1×CD137×CTLA-4 TsAbs demonstrated lower T m values, perhaps due to weaker intrinsic stability of the parental mAbs. The specificity designs do in some cases lead to decreases in Fab T m up to 10°C (Lewis et al., 2014; Wu et al., 2015) . However, for many of the TsAbs, minor peaks with low T m s between 50 and 60°C are apparent that likely result from half-antibody or chain mispairing Fig. S1 .
Binding Properties of the OrthoTsAbs
All the TsAbs were tested for their ability to bind their three respective antigens using surface plasmon resonance (Table II) . Examples of the binding of HER-2, EGFR, and cMet or PD-1, CD137, and CTLA-4 when passed over sensorchip surfaces containing the HER2×EGFR×cMet or the PD-1×CD137×CTLA-4 TsAbs, respectively, are shown in Fig. 4A , B. Binding of all three antigens is apparent for all the TsAbs except the C_HL variants. Somehow, dually tethering the anti-cMet or anti-CTLA-4 Fabs at the C-terminus of the TsAb hinders the on-rate of the antigen significantly so that very little binding is observed (Fig. 4A, B and Table II) . Releasing the dual tethering within the C_L format improves binding to the C-terminal Fab moiety; however, the fastest on-rates for cMet and CTLA-4 are to the TsAbs with N-terminal Fabs (N_H and N_L), which are the only formats without a polypeptide linkage to the N-terminus of the VH or VL domains of these Fabs (Fig. 4A, B) . While the level of antigen bound to each of the TsAbs appears to differ based on the format, the apparent dissociation kinetics for each antigen appears similar across all formats, except for the anti-CTLA-4 binding Half-antibody % was determined based on the non-deconvoluted intensity of the half-antibody divided by the non-deconvoluted intensity of the full-length TsAb.
c n.d. = none detected. For TsAb_HHH and TsAb_HHL, half-antibody is not a possible by-product. Values for pertuzumab were reported previously (Lewis et al. 2014). with Fabs that had an N-terminal tether. Somehow, adding an N-terminal tether impacts both association and dissociation of CTLA-4 to the ipilimumab Fab and this appears to be an antigen/epitopespecific phenomenon. Lastly, varying the order of antigen addition did not impact the kinetics of antigen binding for any of the TsAbs. An example of varying the order of antigen addition is shown for the HHH TsAbs in Fig. 4C , D. Overall, every TsAb format demonstrated strong trispecific binding except the C_HL format whose kinetic onrate was hindered by dual tethering.
Discussion
The OrthoTsAbs described here are an encouraging novel class of moieties that use native-like antibody Fab domains, as opposed to antibody Fv, domain antibody or alternative scaffold proteins, to achieve multivalent binding. Given the very low theoretical assembly levels expected in the absence of interface designs (<2% for the IgG Fc-containing OrthoTsAbs), the level of correct assembly achieved within these initial proof-of-concept TsAbs is extraordinarily high. Ultimately, it would be important for each format to reach >80% correct assembly to allow them to be produced without complex post-expression purification schemes. Promisingly, half of the TsAbs demonstrated >80% correct HC/LC and HC/HC assembly with a few >90%; however, all the Fc-containing TsAbs demonstrated between 10 and 50% half-antibody, which would also need to be removed during manufacturing. N-terminally or C-terminally tethering Fabs to one of the HCs generally resulted in the HC without the tethered Fab expressing at a higher level, which led to half-antibody (Fig. 3A) . This half-antibody lacks the designed heterodimer interactions within the CH3 that stabilize the domain, which we believe reveals itself with lower T m peaks within the DSC curves of the Fccontaining TsAbs that contain between 10 and 50% half-antibody. Additional engineering or design work within the HC/LC and CH3 interfaces is likely necessary within most of the constructs to reduce these impurities to make them acceptable from a manufacturing perspective. Additionally, one or more of the parental mAbs may be Fig. 4 Evaluation of the 'tri-specificity' of the OrthoTsAbs. Triple antigen binding was tested using soluble, monomeric extracellular antigen domains. The top panels are the double-referenced surface plasmon resonance binding curves for soluble, monomeric extracellular HER-2, EGFR, and cMet proteins flowed in various sequence over a sensor chip surface containing the HER-2xEGFRxcMet TsAb_HHH protein (A) or the binding curves for soluble, monomeric extracellular CTLA-4, PD-1 and CD137 proteins flowed in various sequence over a surface containing the PD-1×CD137×CTLA-4 TsAb_HHH (B). The bottom panels contain similar binding curves for all six HER-2×EGFRxcMet TsAbs (C) and all six PD-1×CD137×CTLA-4 TsAbs (D) engineered to improve their expression and stability to equalize these attributes within the parental mAbs. Such efforts may help reduce the final expressed levels of mispaired and half-antibody products even before purification. Also, once a particular format is chosen, other purification techniques may be applied such as hydrophobic interaction chromatography, ion exchange chromatography, or even mixed modal resins to reduce impurities. These have been used to eliminate mispairings and half-antibody for BsAbs, but these methods have to be individually tailored for each construct and thus are to be applied once a particular format (Fig. 1) has been chosen for further characterization (Giese et al., 2017) . Interestingly, we observed there can be an impact on antigen binding when Fabs within the OrthoTsAb formats are recombinantly tethered at their VH or VL N-termini (Table II) . This is similar to what was observed for the DVD-Ig format (Digiammarino et al., 2011) ; however, only the C_HL format with dual tethering demonstrated kinetic on-rates impacted to the same extent as dually tethered DVD-Igs. The impact is most prevalent in the on-rate, although even off-rates were impacted for CTLA-4 binding even for TsAbs with single N-terminal tethers. These effects appear to be antigen-specific as only the dually tethered TsAb had a decrease in kinetic on-rate for cMet binding within the HER-2×EGFR×cMet TsAbs and EGFR and CD137 binding remained unperturbed across all the TsAbs even with some of these Fabs having an N-terminal tether. DVD-Ig on-rates can be improved by modifying the linker composition (Digiammarino et al., 2011) . Modification of linker composition for the TsAbs described here seems like a good next design step to improve the kinetic on-rates for each of the binding moieties.
In summary, we look forward to evaluating the therapeutic possibilities provided by these OrthoTsAbs. Improvements in cellspecific binding, receptor cross-linking, the blockade of tumor escape mechanisms, and immune cell redirection could have a big impact in many disease indications.
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